Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by HC Wainwright from $54.00 to $60.00 in a research report released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.75) EPS and FY2029 earnings at ($0.57) EPS.

A number of other research firms have also recently commented on KYMR. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BTIG Research began coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Finally, Guggenheim lifted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.69.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $31.35 on Friday. The firm has a market cap of $2.03 billion, a P/E ratio of -13.40 and a beta of 2.18. Kymera Therapeutics has a fifty-two week low of $29.16 and a fifty-two week high of $53.27. The firm has a 50-day simple moving average of $39.02 and a two-hundred day simple moving average of $43.75.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities research analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Kymera Therapeutics in the fourth quarter worth about $4,610,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $55,000. Woodline Partners LP increased its holdings in shares of Kymera Therapeutics by 2.3% during the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock valued at $21,621,000 after acquiring an additional 12,334 shares in the last quarter. Vident Advisory LLC acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $236,000. Finally, State of Wyoming acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $45,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.